These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 22355343)

  • 21. Attenuation and protective efficacy of an O-antigen-deficient mutant of Francisella tularensis LVS.
    Li J; Ryder C; Mandal M; Ahmed F; Azadi P; Snyder DS; Pechous RD; Zahrt T; Inzana TJ
    Microbiology (Reading); 2007 Sep; 153(Pt 9):3141-3153. PubMed ID: 17768257
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain.
    Bakshi CS; Malik M; Mahawar M; Kirimanjeswara GS; Hazlett KR; Palmer LE; Furie MB; Singh R; Melendez JA; Sellati TJ; Metzger DW
    Vaccine; 2008 Sep; 26(41):5276-88. PubMed ID: 18692537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Francisella tularensis Live Vaccine Strain deficient in capB and overexpressing the fusion protein of IglA, IglB, and IglC from the bfr promoter induces improved protection against F. tularensis respiratory challenge.
    Jia Q; Bowen R; Lee BY; Dillon BJ; Masleša-Galić S; Horwitz MA
    Vaccine; 2016 Sep; 34(41):4969-4978. PubMed ID: 27577555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of Inner and Outer Membrane Proteins from
    Post DMB; Slütter B; Schilling B; Chande AT; Rasmussen JA; Jones BD; D'Souza AK; Reinders LM; Harty JT; Gibson BW; Apicella MA
    mBio; 2017 Oct; 8(5):. PubMed ID: 29018123
    [No Abstract]   [Full Text] [Related]  

  • 25. Genetic modification of the O-polysaccharide of Francisella tularensis results in an avirulent live attenuated vaccine.
    Kim TH; Pinkham JT; Heninger SJ; Chalabaev S; Kasper DL
    J Infect Dis; 2012 Apr; 205(7):1056-65. PubMed ID: 21969334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low dose vaccination with attenuated Francisella tularensis strain SchuS4 mutants protects against tularemia independent of the route of vaccination.
    Rockx-Brouwer D; Chong A; Wehrly TD; Child R; Crane DD; Celli J; Bosio CM
    PLoS One; 2012; 7(5):e37752. PubMed ID: 22662210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of Francisella tularensis ΔpdpC as a candidate live attenuated vaccine against respiratory challenge by a virulent SCHU P9 strain of Francisella tularensis in a C57BL/6J mouse model.
    Tian D; Uda A; Park ES; Hotta A; Fujita O; Yamada A; Hirayama K; Hotta K; Koyama Y; Azaki M; Morikawa S
    Microbiol Immunol; 2018 Jan; 62(1):24-33. PubMed ID: 29171073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Further Characterization of the Capsule-Like Complex (CLC) Produced by
    Champion AE; Bandara AB; Mohapatra N; Fulton KM; Twine SM; Inzana TJ
    Front Cell Infect Microbiol; 2018; 8():182. PubMed ID: 29963499
    [No Abstract]   [Full Text] [Related]  

  • 29. A panel of correlates predicts vaccine-induced protection of rats against respiratory challenge with virulent Francisella tularensis.
    De Pascalis R; Hahn A; Brook HM; Ryden P; Donart N; Mittereder L; Frey B; Wu TH; Elkins KL
    PLoS One; 2018; 13(5):e0198140. PubMed ID: 29799870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular immune responses to aerosol challenge with Francisella tularensis in mice inoculated with live vaccine candidates of varying efficacy.
    Shen H; Harris G; Chen W; Sjostedt A; Ryden P; Conlan W
    PLoS One; 2010 Oct; 5(10):e13349. PubMed ID: 20967278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A study of innate immune kinetics reveals a role for a chloride transporter in a virulent Francisella tularensis type B strain.
    Matz LM; Petrosino JF
    Microbiologyopen; 2021 Feb; 10(2):e1170. PubMed ID: 33970545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Perforin- and granzyme-mediated cytotoxic effector functions are essential for protection against Francisella tularensis following vaccination by the defined F. tularensis subsp. novicida ΔfopC vaccine strain.
    Sanapala S; Yu JJ; Murthy AK; Li W; Guentzel MN; Chambers JP; Klose KE; Arulanandam BP
    Infect Immun; 2012 Jun; 80(6):2177-85. PubMed ID: 22493083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monophosphoryl Lipid A Enhances Efficacy of a Francisella tularensis LVS-Catanionic Nanoparticle Subunit Vaccine against F. tularensis Schu S4 Challenge by Augmenting both Humoral and Cellular Immunity.
    Richard K; Mann BJ; Qin A; Barry EM; Ernst RK; Vogel SN
    Clin Vaccine Immunol; 2017 Mar; 24(3):. PubMed ID: 28077440
    [No Abstract]   [Full Text] [Related]  

  • 34. Novel catanionic surfactant vesicle vaccines protect against Francisella tularensis LVS and confer significant partial protection against F. tularensis Schu S4 strain.
    Richard K; Mann BJ; Stocker L; Barry EM; Qin A; Cole LE; Hurley MT; Ernst RK; Michalek SM; Stein DC; Deshong P; Vogel SN
    Clin Vaccine Immunol; 2014 Feb; 21(2):212-26. PubMed ID: 24351755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Passive protection of mice against lethal Francisella tularensis (live tularemia vaccine strain) infection by the sera of human recipients of the live tularemia vaccine.
    Drabick JJ; Narayanan RB; Williams JC; Leduc JW; Nacy CA
    Am J Med Sci; 1994 Aug; 308(2):83-7. PubMed ID: 8042659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of a live attenuated vaccine candidate for tularemia prophylaxis.
    Mahawar M; Rabadi SM; Banik S; Catlett SV; Metzger DW; Malik M; Bakshi CS
    PLoS One; 2013; 8(4):e61539. PubMed ID: 23613871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tularemia in BALB/c and C57BL/6 mice vaccinated with Francisella tularensis LVS and challenged intradermally, or by aerosol with virulent isolates of the pathogen: protection varies depending on pathogen virulence, route of exposure, and host genetic background.
    Chen W; Shen H; Webb A; KuoLee R; Conlan JW
    Vaccine; 2003 Sep; 21(25-26):3690-700. PubMed ID: 12922099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cellular and humoral immunity are synergistic in protection against types A and B Francisella tularensis.
    Sebastian S; Pinkham JT; Lynch JG; Ross RA; Reinap B; Blalock LT; Conlan JW; Kasper DL
    Vaccine; 2009 Jan; 27(4):597-605. PubMed ID: 19022323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccination with a defined Francisella tularensis subsp. novicida pathogenicity island mutant (DeltaiglB) induces protective immunity against homotypic and heterotypic challenge.
    Cong Y; Yu JJ; Guentzel MN; Berton MT; Seshu J; Klose KE; Arulanandam BP
    Vaccine; 2009 Sep; 27(41):5554-61. PubMed ID: 19651173
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Francisella tularensis Schu S4 purine auxotroph is highly attenuated in mice but offers limited protection against homologous intranasal challenge.
    Pechous RD; McCarthy TR; Mohapatra NP; Soni S; Penoske RM; Salzman NH; Frank DW; Gunn JS; Zahrt TC
    PLoS One; 2008 Jun; 3(6):e2487. PubMed ID: 18575611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.